SCHEMBL20435596

SCHEMBL20435596

O=C(Nc1ccc(Cl)cn1)c1ccc(I)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.73
SMN1; SMN2 Q16637 6/20 0.73
NFKB1 P19838 2/20 0.73
NFKB2 Q00653 2/20 0.73
RELA Q04206 2/20 0.73
TSHR P16473 2/20 0.73
TP53 P04637 2/20 0.73
NPC1 O15118 7/20 0.64
KMT2A Q03164 5/20 0.64
MEN1 O00255 3/20 0.64
CASP3 P42574 2/20 0.64
SENP8 Q96LD8 2/20 0.64
SENP7 Q9BQF6 2/20 0.64
SENP6 Q9GZR1 2/20 0.64
DEGS1 O15121 1/20 0.62
ALDH1A1 P00352 2/20 0.61
LMNA P02545 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.60
F10 P00742 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3409610 0.84 RAB9A (0.73) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL29858775 0.84 RAB9A (0.73) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL7069217 0.84 KMT2A (0.79) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL20284468 0.83 DEGS1 (0.68) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL28265311 0.81 RAB9A (0.68) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL12501925 0.81 RAB9A (0.72) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL28665240 0.79 RAB9A (0.85) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL3164078 0.79 SORT1 (0.56) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL1991606 0.78 TRPV1 (0.65) RAB9ASMN1; SMN2NPC1KMT2AMEN1
SCHEMBL4618184 0.78 TRPV1 (0.65) RAB9ASMN1; SMN2NPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 US disclosed
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans KCL THERAPEUTICS, INC. (US) 2022-05-10 US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 US disclosed
WO-2019104201-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS Zander Therapeutics, Inc. (US) 2019-05-31 WO disclosed
WO-2019104199-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY REGEN BIOPHARMA INC. (US) 2019-05-31 WO disclosed
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals Zander Therapeutics, Inc. 2019-02-21 US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 RAB9A 3645/4885SMN1; SMN2 2344/4885NFKB1 574/4885
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 RAB9A 3469/4885SMN1; SMN2 2285/4885NFKB1 650/4885
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals NR4A2, NR2C2, NR0B2 RAB9A 3469/4885SMN1; SMN2 2285/4885NFKB1 650/4885
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans NR4A2, NR2C2, NR0B2 RAB9A 3645/4885SMN1; SMN2 2344/4885NFKB1 574/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 RAB9A 3762/4885SMN1; SMN2 2982/4885NFKB1 557/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 RAB9A 3469/4885SMN1; SMN2 2285/4885NFKB1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.